naproxen has been researched along with milrinone in 2 studies
| Studies (naproxen) | Trials (naproxen) | Recent Studies (post-2010) (naproxen) | Studies (milrinone) | Trials (milrinone) | Recent Studies (post-2010) (milrinone) |
|---|---|---|---|---|---|
| 4,551 | 1,057 | 1,429 | 1,605 | 235 | 452 |
| Protein | Taxonomy | naproxen (IC50) | milrinone (IC50) |
|---|---|---|---|
| Phosphodiesterase | Bos taurus (cattle) | 1 | |
| cGMP-dependent 3',5'-cyclic phosphodiesterase | Homo sapiens (human) | 0.3 | |
| High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8A | Homo sapiens (human) | 0.3 | |
| cGMP-specific 3',5'-cyclic phosphodiesterase | Homo sapiens (human) | 0.52 | |
| Prostaglandin G/H synthase 1 | Homo sapiens (human) | 4.7 | |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4A | Homo sapiens (human) | 6 | |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4B | Homo sapiens (human) | 6 | |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4C | Homo sapiens (human) | 6 | |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4D | Homo sapiens (human) | 3.15 | |
| cGMP-inhibited 3',5'-cyclic phosphodiesterase B | Homo sapiens (human) | 1.8674 | |
| cGMP-inhibited 3',5'-cyclic phosphodiesterase A | Homo sapiens (human) | 1.8177 | |
| cGMP-specific 3',5'-cyclic phosphodiesterase | Bos taurus (cattle) | 5 | |
| Phosphodiesterase | Sus scrofa (pig) | 0.843 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for naproxen and milrinone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for naproxen and milrinone
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |